急性髓性白血病将治疗性WT1特异性CD8 TCR-T细胞倾斜到一种类似NK的表型,影响功能和持久性
Francesco Mazziotta1,2,3, Lauren E Martin1, Daniel N Eagan2,4
1Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
medRxiv : the preprint server for health sciences
|January 7, 2025
概括
针对复发性急性骨髓性白血病 (AML) 的全源性造血细胞移植 (HCT) 与T细胞免疫疗法取得了有限的成功. 虽然观察到T细胞持久性,但AML诱导的功能障碍影响了结果,需要新的治疗策略.
科学领域:
- 免疫治疗是一种免疫疗法.
- 造血细胞移植 造血细胞移植
- 急性髓性白血病研究研究
背景情况:
- 复发性/耐药性急性髓性白血病 (AML) 在异构造血细胞移植 (HCT) 后的预后不佳.
- 以前的研究表明,工程T细胞受体 (TCR) T细胞可以防止HCT后AML复发.
- 目前的研究调查了TTCR-C4转Epstein-Barr病毒 (EBV) 或细胞巨乳病毒 (CMV) 特定的T细胞在HCT后活跃疾病患者的疗效.
研究的目的:
- 评估EBV或CMV特异性TTCR-C4 T细胞在HCT后AML活性患者中的治疗潜力.
- 为了研究输液后TTCR-C4转T细胞的持久性和分化特征.
- 了解T细胞功能障碍的机制在AML复发后HCT的背景下.
主要方法:
- 输注EBV或CMV特异性TTCR-C4转T细胞给15名患有HCT后AML活性的患者.
- 监测T细胞持久性和表型,包括分化状态和耗尽标记.
- 分析T细胞形状与临床结果之间的相关性,包括疾病控制.
主要成果:
- 输注EBV或CMV特异性TTCR-C4 T细胞并没有显著改善HCT后AML活性患者的结果.
- 与CMV特异性T细胞相比,TTCR-C4转的EBV特异性T细胞的持续时间更长.
- 持久的TTCR-C4 T细胞表现出功能障碍的自然杀手类终端分化,与固体瘤T细胞耗尽模式不同.
- 一名患者通过持续的TTCR-C4效应器-记忆T细胞实现了长期疾病控制.
结论:
- 针对AML复发后HCT的工程T细胞免疫疗法面临着由于AML诱导的T细胞功能障碍的挑战.
- 持久TTCR-C4 T细胞的独特分化特征表明AML中免疫逃避的独特机制.
- 需要进一步的研究来克服T细胞功能障碍,并改进治疗策略后HCTAML复发.
更多相关视频
05:24Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021
4.1K
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
13.9K
相关概念视频
Cytotoxic T Cells-mediated Immune Response
841
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
841
T Cell Activation and Clonal Selection
651
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
651
T Cell Types and Functions
946
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
946
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
